BATM H1 Adj. Operating Profit Declines

BATM Advanced Communications Limited (BVC.L) reported that its first half adjusted operating profit for ongoing operations declined to $1.5 million from $6.7 million, prior year, primarily due to the lower revenue from COVID-19 products. Adjusted gross margin was 31.6% compared to 38.4%, last year.

Net profit after tax attributable to equity holders of the parent was $0.1 million compared to $12.0 million, previous year. Profit per share, in cents, was 0.03 compared to 2.70.

Total Group revenue for ongoing operations was $57.5 million compared to $64.2 million, prior year, with growth in the Networking & Cyber division being offset by a reduction in the Bio-Medical division, primarily reflecting lower sales in the Diagnostic unit as well as the impact of the strengthening of the US dollar. On a constant currency basis, revenue for ongoing operations for the first half was $61.1 million.

Looking forward, the Group said it remains on track to deliver revenues for full year 2022 in line with market expectations.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional... Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton.
Follow RTT